4889 — Renascience Income Statement
0.000.00%
Last trade - 00:00- ¥13bn
- ¥11bn
- ¥194m
Annual income statement for Renascience, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | Yuho | Yuho | Yuho |
| Standards: | JAS | JAS | JAS | JAS | JAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 72 | 210 | 139 | 101 | 194 |
| Cost of Revenue | |||||
| Gross Profit | 52 | 180 | 81 | 100 | 166 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 255 | 305 | 361 | 434 | 451 |
| Operating Profit | -183 | -95.2 | -222 | -334 | -257 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -184 | -99.8 | -253 | -334 | -256 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -184 | -100 | -254 | -336 | -258 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -184 | -100 | -254 | -336 | -258 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -184 | -100 | -254 | -336 | -258 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -15 | -7.68 | -19.4 | -26.4 | -20.1 |
| Dividends per Share |